JP5727236B2 - 抗がん製剤 - Google Patents

抗がん製剤 Download PDF

Info

Publication number
JP5727236B2
JP5727236B2 JP2011000720A JP2011000720A JP5727236B2 JP 5727236 B2 JP5727236 B2 JP 5727236B2 JP 2011000720 A JP2011000720 A JP 2011000720A JP 2011000720 A JP2011000720 A JP 2011000720A JP 5727236 B2 JP5727236 B2 JP 5727236B2
Authority
JP
Japan
Prior art keywords
acid
bis
carboxyphenoxy
formulation
bdph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011000720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011173866A5 (https=
JP2011173866A (ja
Inventor
チオウ，ツィー−ウェン
ハーン，ホルン−ジゥ
リン，シン−ゾン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Dong Hwa University
Original Assignee
National Dong Hwa University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Dong Hwa University filed Critical National Dong Hwa University
Publication of JP2011173866A publication Critical patent/JP2011173866A/ja
Publication of JP2011173866A5 publication Critical patent/JP2011173866A5/ja
Application granted granted Critical
Publication of JP5727236B2 publication Critical patent/JP5727236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011000720A 2010-01-05 2011-01-05 抗がん製剤 Active JP5727236B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29231110P 2010-01-05 2010-01-05
US61/292,311 2010-01-05

Publications (3)

Publication Number Publication Date
JP2011173866A JP2011173866A (ja) 2011-09-08
JP2011173866A5 JP2011173866A5 (https=) 2013-12-19
JP5727236B2 true JP5727236B2 (ja) 2015-06-03

Family

ID=43801814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011000720A Active JP5727236B2 (ja) 2010-01-05 2011-01-05 抗がん製剤

Country Status (5)

Country Link
US (2) US20110165201A1 (https=)
EP (1) EP2343051B1 (https=)
JP (1) JP5727236B2 (https=)
DK (1) DK2343051T3 (https=)
ES (1) ES2522167T3 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
TWI472519B (zh) * 2011-12-20 2015-02-11 Nat Univ Dong Hwa 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能
US8927601B2 (en) * 2011-12-20 2015-01-06 National Dong Hwa University Uses of N-butylidenephthalide in treating a liver injury and improving liver function
TWI522099B (zh) * 2014-06-04 2016-02-21 中國醫藥大學 治療胰臟癌之醫藥配方及其應用
TWI511727B (zh) 2014-07-02 2015-12-11 Everfront Biotech Inc 苯酞化合物之應用
NZ728386A (en) * 2014-07-04 2018-02-23 Everfront Biotech Inc Use of phthalide compound
JP6371898B2 (ja) * 2014-07-28 2018-08-08 易珈生技股▲ふん▼有限公司 ブチリデンフタリドの用途、その使用方法及びそれを使用して医薬組成物を製造する方法
CN112451519A (zh) * 2014-07-28 2021-03-09 长弘生物科技股份有限公司 丁烯基苯酞的用途及将其制备为医药组合物的方法
ES2850498T3 (es) * 2016-05-23 2021-08-30 Everfront Biotech Inc Uso de Z-butilidenftalida en la activación del sistema autoinmune
CN113425707B (zh) * 2021-07-30 2022-12-30 青岛大学附属医院 壬二酸预防蒽环类抗肿瘤药物心肌毒性的应用
IT202300013839A1 (it) * 2023-07-04 2025-01-04 Akeso S R L Composizione cosmetica contenente microsfere di chitosano e acido azelaico funzionalizzate con olio ozonizzato
IT202300013845A1 (it) * 2023-07-04 2025-01-04 Akeso S R L Composizione cosmetica contenente microsfere di chitosano e acido azelaico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
WO2003072143A1 (en) 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
GB0318682D0 (en) 2003-08-08 2003-09-10 Novartis Ag Organic compounds
US20050255060A1 (en) * 2004-05-10 2005-11-17 Oblong John E Personal care compositions and methods regulating mammalian hair growth
TWI298259B (en) * 2004-10-08 2008-07-01 Tzu Chi Buddhist General Hospital Pharmaceutical composition for inhibiting/treating brain cancer
CA2615200A1 (en) * 2008-01-03 2009-07-03 National Research Council Canada Use of alkylphthalides for inducing phase 2 proteins

Also Published As

Publication number Publication date
ES2522167T3 (es) 2014-11-13
US20150216836A1 (en) 2015-08-06
US20110165201A1 (en) 2011-07-07
DK2343051T3 (da) 2014-10-27
EP2343051B1 (en) 2014-07-30
JP2011173866A (ja) 2011-09-08
US9585864B2 (en) 2017-03-07
EP2343051A2 (en) 2011-07-13
EP2343051A3 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
JP5727236B2 (ja) 抗がん製剤
Dong et al. Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy
Yan et al. Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses
Zhao et al. Post-resection treatment of glioblastoma with an injectable nanomedicine-loaded photopolymerizable hydrogel induces long-term survival
Ling et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
Chen et al. Paclitaxel loaded phospholipid-based gel as a drug delivery system for local treatment of glioma
US10765638B2 (en) Particle formulation with polycation complex
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
Cenni et al. The effect of poly (d, l-lactide-co-glycolide)-alendronate conjugate nanoparticles on human osteoclast precursors
Shen et al. Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells
TW201106947A (en) Anticancer formulation
Tu et al. Berberine enhances the function of intestinal stem cells in healthy and radiation-injured mice
Ma et al. Immunoregulatory Engineering of Semiconducting Charge‐Reversal Nanoantioxidant for Ameliorating Cancer Radioimmunotheranostics
Famta et al. Establishment and evaluation of paclitaxel and simvastatin-laden nanofibers for post-surgical tumor recurrence in breast cancer
CN106924301B (zh) 灵芝提取物和灵芝三萜单体在治疗常染色体显性遗传多囊肾病中的应用
EP3989963A1 (en) Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells
EP4230205B1 (en) Polyethylene glycol-modified irinotecan and temozolomide compositions
CN106236699A (zh) 一种抗肿瘤缓释植入剂及其制备方法
Mohaghegh et al. Immunoengineering strategies using nanoparticles for obesity treatment
Liu et al. Enhanced glioblastoma selectivity of harmine via the albumin carrier
Cao et al. ROS-triggered and macrophage-targeted micelles modulate mitochondria function and polarization in obesity
Wang et al. Targeted liposomes for macrophages-mediated pulmonary fibrosis therapy
CN108324952B (zh) 金簇分子的新应用
CN117838853A (zh) 马普替林与ctla4抗体联用在制备抗肿瘤药物中的应用
Pankaj Formulation and evaluation of implantable drug delivery system of dacarbazine by using hydrophilic polymer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150402

R150 Certificate of patent or registration of utility model

Ref document number: 5727236

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250